Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Richard Tuli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0001-2360-4179; OpenAlex author ID A5024750927. Sources: ClinicalTrials.gov.

Their work

Papers
32 (first author 1, last author 10)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
104
Papers, trials and grants by year

2012: 3 papers · 2013: 1 trial · 2014: 4 papers · 2015: 2 papers · 2016: 4 papers · 2017: 4 papers · 2018: 3 papers · 2019: 6 papers · 2020: 4 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 32

  1. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Co-author DOI 10.1016/j.ijrobp.2024.10.026↗
  2. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2021.0057↗
  3. Duration of therapy for locally advanced pancreatic cancer: Does it matter? Co-author DOI 10.1002/cam4.3081↗
  4. Six-dimensional quantitative DCE MR Multitasking of the entire abdomen: Method and application to pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/mrm.28167↗
  5. Quantifying vascular invasion in pancreatic cancer-a contrast CT based method for surgical resectability evaluation. Last author DOI 10.1088/1361-6560/ab8106↗
  6. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unres… Co-author DOI 10.4103/eus.eus_44_19↗
  7. Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers. Last author DOI 10.1016/j.adro.2018.10.006↗
  8. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2018.12.060↗
  9. Stromal hyaluronan accumulation is associated with low tumor grade and nodal metastases in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2019.05.004↗
  10. Combined morphologic and metabolic pipeline for Positron emission tomography/computed tomography based radiotherapy response evaluation in locally advanced pan… Last author DOI 10.1016/j.phro.2018.12.003↗
  11. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2019.06.016↗
  12. Pancreatic cancer 'mismatch' in Lynch syndrome. Co-author DOI 10.1136/bmjgast-2019-000274↗
  13. An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice. Co-author DOI 10.1053/j.gastro.2018.08.028↗
  14. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Co-author DOI 10.1186/s40169-018-0210-9↗
  15. Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. Co-author DOI 10.21037/jgo.2017.11.10↗
  16. Private Funding for Pancreatic Cancer Research: More Than a Chip Shot. Last author DOI 10.1053/j.gastro.2017.02.034↗
  17. Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.17.00016↗
  18. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy. Last author DOI 10.1245/s10434-017-6076-z↗
  19. Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. Last author DOI 10.21037/jgo.2016.12.04↗
  20. Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma. Last author DOI 10.1371/journal.pone.0152172↗
  21. Targeting mTOR in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2016.00099↗
  22. Meta-analyses of treatment standards for pancreatic cancer. First author DOI 10.3892/mco.2015.716↗
  23. Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy. Last author DOI 10.3978/j.issn.2078-6891.2015.109↗
  24. Four-Dimensional Magnetic Resonance Imaging With 3-Dimensional Radial Sampling and Self-Gating-Based K-Space Sorting: Early Clinical Experience on Pancreatic C… Co-author DOI 10.1016/j.ijrobp.2015.08.028↗
  25. Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation therapy for pancreatic cancer. Last author DOI 10.1016/j.meddos.2014.09.001↗
  26. Management options in locally advanced pancreatic cancer. Co-author DOI 10.1007/s11912-014-0388-y↗
  27. Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888. Co-author DOI 10.1016/j.tranon.2014.04.003↗
  28. Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma. Last author DOI 10.3389/fphys.2014.00087↗
  29. Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Co-author DOI 10.3389/fphys.2014.00088↗
  30. Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Co-author DOI 10.1016/j.prro.2011.06.009↗
  31. Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: impli… Co-author DOI 10.1016/j.radonc.2012.07.004↗
  32. Development of a novel preclinical pancreatic cancer research model: bioluminescence image-guided focal irradiation and tumor monitoring of orthotopic xenograf… Co-author DOI 10.1593/tlo.11316↗

Trials 1

  1. Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer Principal investigator NCT01908478↗

Closest collaborators

The 25 strongest of 104 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew Eugene Hendifar · 19 shared papers, 2014–2020 · strength 1.59
  2. Joseph M. Herman · 8 shared papers, 2012–2025 · strength 0.53
  3. Nicholas N. Nissen · 8 shared papers, 2014–2019 · strength 0.50
  4. Wensha Yang · 6 shared papers, 2015–2020 · strength 0.48
  5. John David · 4 shared papers, 2019–2020 · strength 0.47
  6. Simon K. Lo · 5 shared papers, 2014–2020 · strength 0.38
  7. Jun Gong · 4 shared papers, 2016–2019 · strength 0.34
  8. Arsen Osipov · 5 shared papers, 2016–2019 · strength 0.33
  9. Marsha Reyngold · 2 shared papers, 2021–2025 · strength 0.29
  10. William Adrian Hall · 2 shared papers, 2019–2025 · strength 0.27
  11. Karyn A. Goodman · 2 shared papers, 2019–2025 · strength 0.27
  12. Zhaoyang Fan · 3 shared papers, 2015–2020 · strength 0.26
  13. Zhigang Zhang · 2 shared papers, 2020–2021 · strength 0.25
  14. Eileen Mary O'Reilly · 2 shared papers, 2020–2021 · strength 0.25
  15. Brent K. Larson · 2 shared papers, 2019 · strength 0.23
  16. Michelle Guan · 2 shared papers, 2019 · strength 0.23
  17. Yi Lao · 2 shared papers, 2019–2020 · strength 0.21
  18. Amol Kumar Narang · 2 shared papers, 2012–2025 · strength 0.21
  19. Stephen Jacob Pandol · 3 shared papers, 2014–2020 · strength 0.21
  20. Theodore Sunki Hong · 1 shared paper, 2025 · strength 0.19
  21. Michael Frederick Bassetti · 1 shared paper, 2025 · strength 0.19
  22. Bradley A. Erickson · 1 shared paper, 2025 · strength 0.19
  23. Nina Niu Sanford · 1 shared paper, 2025 · strength 0.19
  24. Michael David Chuong · 1 shared paper, 2025 · strength 0.19
  25. Todd Anthony Aguilera · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.